191 related articles for article (PubMed ID: 29848589)
1. Partial Inactivation of the Chromatin Remodelers SMARCA2 and SMARCA4 in Virus-Infected Cells by Caspase-Mediated Cleavage.
Dudek AH; Pfaff F; Bolte H; Waguia Kontchou C; Schwemmle M
J Virol; 2018 Aug; 92(16):. PubMed ID: 29848589
[TBL] [Abstract][Full Text] [Related]
2. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
[TBL] [Abstract][Full Text] [Related]
3. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation.
Wilson BG; Helming KC; Wang X; Kim Y; Vazquez F; Jagani Z; Hahn WC; Roberts CW
Mol Cell Biol; 2014 Mar; 34(6):1136-44. PubMed ID: 24421395
[TBL] [Abstract][Full Text] [Related]
4. SWI/SNF Complex-deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract: A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2.
Agaimy A; Daum O; Märkl B; Lichtmannegger I; Michal M; Hartmann A
Am J Surg Pathol; 2016 Apr; 40(4):544-53. PubMed ID: 26551623
[TBL] [Abstract][Full Text] [Related]
5. High expression of SMARCA4 or SMARCA2 is frequently associated with an opposite prognosis in cancer.
Guerrero-Martínez JA; Reyes JC
Sci Rep; 2018 Feb; 8(1):2043. PubMed ID: 29391527
[TBL] [Abstract][Full Text] [Related]
6. Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type.
Jelinic P; Schlappe BA; Conlon N; Tseng J; Olvera N; Dao F; Mueller JJ; Hussein Y; Soslow RA; Levine DA
Mod Pathol; 2016 Jan; 29(1):60-6. PubMed ID: 26564006
[TBL] [Abstract][Full Text] [Related]
7. The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.
Vangamudi B; Paul TA; Shah PK; Kost-Alimova M; Nottebaum L; Shi X; Zhan Y; Leo E; Mahadeshwar HS; Protopopov A; Futreal A; Tieu TN; Peoples M; Heffernan TP; Marszalek JR; Toniatti C; Petrocchi A; Verhelle D; Owen DR; Draetta G; Jones P; Palmer WS; Sharma S; Andersen JN
Cancer Res; 2015 Sep; 75(18):3865-3878. PubMed ID: 26139243
[TBL] [Abstract][Full Text] [Related]
8. Loss of expression of SMARCA4 (BRG1), SMARCA2 (BRM) and SMARCB1 (INI1) in undifferentiated carcinoma of the endometrium is not uncommon and is not always associated with rhabdoid morphology.
Ramalingam P; Croce S; McCluggage WG
Histopathology; 2017 Feb; 70(3):359-366. PubMed ID: 27656868
[TBL] [Abstract][Full Text] [Related]
9. Influenza Virus and Chromatin: Role of the CHD1 Chromatin Remodeler in the Virus Life Cycle.
Marcos-Villar L; Pazo A; Nieto A
J Virol; 2016 Jan; 90(7):3694-707. PubMed ID: 26792750
[TBL] [Abstract][Full Text] [Related]
10. Expression inactivation of SMARCA4 by microRNAs in lung tumors.
Coira IF; Rufino-Palomares EE; Romero OA; Peinado P; Metheetrairut C; Boyero-Corral L; Carretero J; Farez-Vidal E; Cuadros M; Reyes-Zurita FJ; Lupiáñez JA; Sánchez-Cespedes M; Slack FJ; Medina PP
Hum Mol Genet; 2015 Mar; 24(5):1400-9. PubMed ID: 25355421
[TBL] [Abstract][Full Text] [Related]
11. Heterozygous Mutations in SMARCA2 Reprogram the Enhancer Landscape by Global Retargeting of SMARCA4.
Gao F; Elliott NJ; Ho J; Sharp A; Shokhirev MN; Hargreaves DC
Mol Cell; 2019 Sep; 75(5):891-904.e7. PubMed ID: 31375262
[TBL] [Abstract][Full Text] [Related]
12. Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors - a review of patent literature from 2019-30 June 2023.
Reichl KD; Lee ECY; Gopalsamy A
Expert Opin Ther Pat; 2024 Mar; 34(3):159-169. PubMed ID: 38578210
[TBL] [Abstract][Full Text] [Related]
13. Ovarian high-grade serous carcinoma cells with low SMARCA4 expression and high SMARCA2 expression contribute to platinum resistance.
Kido K; Nojima S; Motooka D; Nomura Y; Kohara M; Sato K; Ohshima K; Tahara S; Kurashige M; Umeda D; Takashima T; Kiyokawa H; Ukon K; Matsui T; Okuzaki D; Morii E
J Pathol; 2023 May; 260(1):56-70. PubMed ID: 36763038
[TBL] [Abstract][Full Text] [Related]
14. Manipulation of SMARCA2 and SMARCA4 transcript levels in porcine embryos differentially alters development and expression of SMARCA1, SOX2, NANOG, and EIF1.
Magnani L; Cabot RA
Reproduction; 2009 Jan; 137(1):23-33. PubMed ID: 18845624
[TBL] [Abstract][Full Text] [Related]
15. SMARCA2-deficiency confers sensitivity to targeted inhibition of SMARCA4 in esophageal squamous cell carcinoma cell lines.
Ehrenhöfer-Wölfer K; Puchner T; Schwarz C; Rippka J; Blaha-Ostermann S; Strobl U; Hörmann A; Bader G; Kornigg S; Zahn S; Sommergruber W; Schweifer N; Zichner T; Schlattl A; Neumüller RA; Shi J; Vakoc CR; Kögl M; Petronczki M; Kraut N; Pearson MA; Wöhrle S
Sci Rep; 2019 Aug; 9(1):11661. PubMed ID: 31406271
[TBL] [Abstract][Full Text] [Related]
16. Innate cellular response to virus particle entry requires IRF3 but not virus replication.
Collins SE; Noyce RS; Mossman KL
J Virol; 2004 Feb; 78(4):1706-17. PubMed ID: 14747536
[TBL] [Abstract][Full Text] [Related]
17. SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens.
Herpel E; Rieker RJ; Dienemann H; Muley T; Meister M; Hartmann A; Warth A; Agaimy A
Ann Diagn Pathol; 2017 Feb; 26():47-51. PubMed ID: 28038711
[TBL] [Abstract][Full Text] [Related]
18. SMARCA2-regulated host cell factors are required for MxA restriction of influenza A viruses.
Dornfeld D; Dudek AH; Vausselin T; Günther SC; Hultquist JF; Giese S; Khokhlova-Cubberley D; Chew YC; Pache L; Krogan NJ; Garcia-Sastre A; Schwemmle M; Shaw ML
Sci Rep; 2018 Feb; 8(1):2092. PubMed ID: 29391557
[TBL] [Abstract][Full Text] [Related]
19. Global Regulatory DNA Potentiation by SMARCA4 Propagates to Selective Gene Expression Programs via Domain-Level Remodeling.
Lazar JE; Stehling-Sun S; Nandakumar V; Wang H; Chee DR; Howard NP; Acosta R; Dunn D; Diegel M; Neri F; Castillo A; Ibarrientos S; Lee K; Lescano N; Van Biber B; Nelson J; Halow J; Sandstrom R; Bates D; Urnov FD; Stamatoyannopoulos JA; Funnell APW
Cell Rep; 2020 May; 31(8):107676. PubMed ID: 32460018
[TBL] [Abstract][Full Text] [Related]
20. Alternative translation contributes to the generation of a cytoplasmic subpopulation of the Junín virus nucleoprotein that inhibits caspase activation and innate immunity.
Bostedt L; Fénéant L; Leske A; Holzerland J; Günther K; Waßmann I; Bohn P; Groseth A
J Virol; 2024 Feb; 98(2):e0197523. PubMed ID: 38294249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
